While several ongoing trials are exploring this neo-adjuvant immunotherapy, to the best of our knowledge no trial is investigating two types of neoadjuvant immunotherapy (PDL-1 and CTLA-4 blocking antibodies) in combination with standard concurrent chemoradiotherapy, in the treatment in locally advanced NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.